缺鐵性貧血市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、治療領域、最終用戶、地區和競爭格局分類，2021-2031年

全球缺鐵性貧血市場（包括旨在補充鐵蘊藏量和使血紅蛋白水平正常化的口服和腸外鐵劑等治療方案）預計將從 2025 年的 58.9 億美元成長到 2031 年的 91.8 億美元，複合年成長率為 7.68%。

這一成長主要受慢性疾病負擔加重（需要持續的血液治療）和孕產婦健康問題的影響，同時也受到人們對營養缺乏症認知不斷提高的限制。根據最新的2025年預測，全球15至49歲女性中將有30.7%患有貧血。

市場促進因素

慢性腎臟病(CKD) 和胃腸道疾病負擔的加重是推動市場擴張的主要動力。這些疾病常常抑制鐵的吸收和利用，導致患者需要持續補充鐵劑。例如，在腎臟護理領域，Akebia Therapeutics 公司的「Auryxia」累計在 2024 年全年將實現 1.522 億美元的淨銷售額。同時，人們對孕產婦健康和妊娠相關貧血管理的日益關注也顯著促進了治療方法的普及，政府和衛生機構的指南也越來越重視篩檢和治療。世界衛生組織 (WHO) 的數據顯示，2023 年全球 15 至 49 歲孕婦中，35.5% 患有貧血，這推動了「Accrufer」等新型口服製劑的普及。因此，Shield Therapeutics 公司 2024 年的銷售額達到 2,930 萬美元，年增 153%。

市場挑戰

標準補鐵療法的不利事件是全球缺鐵性貧血市場擴張的直接且重大障礙。口服鐵劑常引起嚴重的腸胃問題，導致患者依從性低，早期停藥。靜脈靜脈注射有超敏反應的風險，且需要臨床監測，這造成了物流障礙，限制了產品的分銷，尤其是在資源匱乏的環境中。這些安全性和耐受性問題使得市場無法充分滿足高風險族群（例如全球15-49歲孕婦35.5%患有貧血）的迫切治療需求。因此，有效補鐵療法的普及程度有限，阻礙了整體市場收入潛力。

市場趨勢

由於臨床上對更有效率治療方案的需求，以及透過單次給藥完成補鐵以減少住院次數的需求，高劑量靜脈注射鐵劑療法的應用正在加速成長。這顯著提高了門診治療的效率，並體現在Pharmacosmos公司超過30億丹麥克朗的年銷售額上，這主要得益於其高劑量單球製劑在全球範圍內的廣泛應用。同時，專利到期有限公司報告稱，在此期間，其鐵劑產品的銷售額達到5.27億美元，儘管面臨來自學名藥日益激烈的競爭，仍實現了銷售成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球缺鐵性貧血市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（口服鐵劑治療、腸外鐵劑治療、紅血球輸注等）
  • 治療領域（婦產科、腫瘤科、鬱血性心臟衰竭、發炎性腸道疾病、腎臟疾病、其他）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美缺鐵性貧血市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲缺鐵性貧血市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區缺鐵性貧血市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲缺鐵性貧血市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲缺鐵性貧血市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球缺鐵性貧血市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AbbVie Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Amgen Inc.
• Bayer AG
• Fresenius Kabi AG
• Vifor Pharma Group
• Glenmark Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Iron Deficiency Anemia Market, comprising therapeutic solutions like oral and parenteral iron formulations aimed at replenishing iron stores and normalizing hemoglobin levels, is projected to grow from USD 5.89 Billion in 2025 to USD 9.18 Billion by 2031, exhibiting a 7.68% CAGR. This growth is primarily driven by the escalating burden of chronic diseases and maternal health conditions necessitating consistent hematological intervention, alongside increasing awareness of nutritional deficits, with updated 2025 estimates indicating that 30.7% of women aged 15-49 years were affected by anemia globally.

Market Driver

The increasing burden of Chronic Kidney Disease (CKD) and gastrointestinal disorders serves as a primary catalyst for market expansion, as these conditions frequently disrupt iron absorption and utilization, necessitating consistent iron supplementation for patients, exemplified by Akebia Therapeutics' Auryxia generating $152.2 million in net product revenues for full year 2024 in the renal care space. Concurrently, a heightened focus on maternal health and the management of pregnancy-related anemia significantly propels therapeutic adoption, with governmental and health organization mandates increasingly prioritizing screening and treatment; the World Health Organization reported that 35.5% of pregnant women aged 15-49 years worldwide were affected by anemia in 2023, which has spurred the uptake of novel oral formulations like Accrufer, reporting 153% year-over-year revenue growth to $29.3 million in 2024 for Shield Therapeutics.

Market Challenge

The adverse event profiles associated with standard iron replacement therapies present a direct and significant impediment to the Global Iron Deficiency Anemia Market's expansion. Oral iron formulations frequently induce severe gastrointestinal distress, leading to patient non-compliance and premature discontinuation, while intravenous administration carries risks of hypersensitivity reactions and necessitates clinical supervision, creating logistical obstacles that limit product uptake, especially in resource-constrained settings. These safety and tolerability issues prevent the market from fully capitalizing on the urgent therapeutic needs of high-risk demographics, such as the 35.5% of pregnant women aged 15-49 years globally affected by anemia, thereby restricting widespread adoption of effective iron therapies and hampering overall market revenue potential.

Market Trends

The market is witnessing an accelerated adoption of high-dose intravenous iron therapies, driven by the clinical need to streamline treatment protocols and minimize hospital visits by enabling complete iron repletion in a single administration, which significantly enhances outpatient efficiency, as reflected in Pharmacosmos' annual revenue surpassing DKK 3 billion, attributed to the global uptake of its high-dose monoferric formulation. Simultaneously, the competitive landscape is being reshaped by the market entry and expansion of biosimilar iron therapeutics, triggered by the expiration of patents for established branded intravenous treatments, which provides cost-effective options for healthcare systems and compels incumbents to adapt strategies, with CSL Limited reporting $527 million in iron product sales for the period, achieving volume growth despite intensifying generic competition.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Amgen Inc.
• Bayer AG
• Fresenius Kabi AG
• Vifor Pharma Group
• Glenmark Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.

Report Scope

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Market, By Therapy Type

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

Iron Deficiency Anemia Market, By Therapy Areas

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

Iron Deficiency Anemia Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Iron Deficiency Anemia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Iron Deficiency Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
  • 5.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Iron Deficiency Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Therapy Areas
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Iron Deficiency Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Therapy Areas
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Iron Deficiency Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Therapy Areas
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Iron Deficiency Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Therapy Areas
      • 6.3.3.2.3. By End User

7. Europe Iron Deficiency Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Therapy Areas
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Iron Deficiency Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Therapy Areas
      • 7.3.1.2.3. By End User
  • 7.3.2. France Iron Deficiency Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Therapy Areas
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Iron Deficiency Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Therapy Areas
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Iron Deficiency Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Therapy Areas
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Iron Deficiency Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Therapy Areas
      • 7.3.5.2.3. By End User

8. Asia Pacific Iron Deficiency Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Therapy Areas
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Iron Deficiency Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Therapy Areas
      • 8.3.1.2.3. By End User
  • 8.3.2. India Iron Deficiency Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Therapy Areas
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Iron Deficiency Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Therapy Areas
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Iron Deficiency Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Therapy Areas
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Iron Deficiency Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Therapy Areas
      • 8.3.5.2.3. By End User

9. Middle East & Africa Iron Deficiency Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Therapy Areas
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Iron Deficiency Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Therapy Areas
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Iron Deficiency Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Therapy Areas
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Iron Deficiency Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Therapy Areas
      • 9.3.3.2.3. By End User

10. South America Iron Deficiency Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Therapy Areas
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Iron Deficiency Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Therapy Areas
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Iron Deficiency Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Therapy Areas
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Iron Deficiency Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Therapy Areas
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Iron Deficiency Anemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Novartis AG
• 15.5. Amgen Inc.
• 15.6. Bayer AG
• 15.7. Fresenius Kabi AG
• 15.8. Vifor Pharma Group
• 15.9. Glenmark Pharmaceuticals Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer